Inhibikase
Industry: Pharmaceuticals
Developer of preventative and curative treatments for infectious diseases that affect more than 100 million patients worldwide. Products under development include treatments for rare diseases, hepatitis B and C, biodefense, respiratory infectious disease and diarrhrea. Product pipeline anticipates FDA clinical trial clearance in 2013 for its treatment to treat the cause of progressive multifocal leukoencephalopathy (PML).
Company website: Inhibikase
